November 15, 2017
Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors
November 01, 2017
Moderna Announces New Collaboration with AstraZeneca to Co-Develop and Co-Commercialize Relaxin mRNA Therapeutic for Heart Failure
October 19, 2017
Moderna Named One of Global Biopharmaceutical Industry’s Top Employers in Science Magazine’s Annual Survey
October 10, 2017
Stephen Berenson Joins Moderna’s Board of Directors
September 26, 2017
Moderna Announces Publication in Molecular Therapy Characterizing Potent Immune Response Generated by Its mRNA Prophylactic Vaccines
September 14, 2017
Moderna Announces Pipeline and Corporate Update
August 03, 2017
Industry Veteran Juan Andres Joins Moderna as Senior Vice President of Late Stage Technical Development and Manufacturing
July 27, 2017
Moncef M. Slaoui, Ph.D. Joins Moderna’s Board of Directors
July 27, 2017
Moderna Provides Update on mRNA Rare Disease Research and Development Strategy
July 13, 2017
Publication in Cell Demonstrates Moderna’s Zika mRNA Vaccine Prevents In Utero Transmission of Zika Virus in Mice, Protects Against Zika-Related Congenital Damage